|Born||23 January 1948|
|Thesis||Multiple sclerosis and the HLA system (1978)|
David Alastair Standish Compston  (born 23 January 1948) is Emeritus professor of Neurology in the Department of Clinical Neurosciences at the University of Cambridge and an Emeritus Fellow of Jesus College, Cambridge.
Compston was educated at Rugby School followed by Middlesex Hospital Medical school where he was awarded a Bachelor of Medicine, Bachelor of Surgery degree.[when?] He completed his PhD on multiple sclerosis and the Human Leukocyte Antigen (HLA) system at the University of London graduating in 1978.
Research and career
Compston's research focuses on the clinical science of human demyelinating disease including the discovery of genetic risk factors for multiple sclerosis and the introduction of alemtuzumab. 
Compston was formerly Professor of Neurology at the University of Wales, president of the European Neurological Society and the Association of British Neurologists, and editor of the journal Brain.
Awards and honours
Compston's work has been recognised by prizes including the Charcot Award; the K-J Zülch Prize; the World Federation of Neurology Medal; the John Dystel Prize; the Richard and Mary Cave Award of the Multiple Sclerosis Society of Great Britain; the Hughlings Jackson Medal; the Galen Medal; and the Association of British Neurologists Medal.
Compston was elected a Fellow of the Royal Society (FRS) in 2016 and appointed Commander of the Order of the British Empire (CBE) in the 2016 New Year Honours. He was elected a Fellow of the Academy of Medical Sciences;[when?] a Foreign Member of the National Academy of Sciences of Germany[when?] and the National Academy of Medicine of the US.[when?]
- Anon (2016). "Professor Alastair Compston FRS". London: Royal Society. Archived from the original on 29 April 2016. One or more of the preceding sentences incorporates text from the royalsociety.org website where:
"All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License." --"Royal Society Terms, conditions and policies". Archived from the original on 25 September 2015. Retrieved 9 March 2016.CS1 maint: bot: original URL status unknown (link)
- "COMPSTON, Prof. (David) Alastair (Standish)". Who's Who. ukwhoswho.com. 2016 (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. (subscription or UK public library membership required) (subscription required)
- "Professor Alastair Compston, Cambridge Neurosciene". Cambridge: University of Cambridge. Archived from the original on 4 March 2015.
- "Prof Alastair Compston, CBE Authorised Biography". Debrett's. Archived from the original on 20 May 2016.
- Compston, David Alistair Standish (1978). Multiple sclerosis and the HLA system (PhD thesis). University of London. OCLC 500408475.
- Jones, Joanne L.; Phuah, Chia-Ling; Cox, Amanda L.; Thompson, Sara A.; Ban, Maria; Shawcross, Jacqueline; Walton, Amie; Sawcer, Stephen J.; Compston, Alastair; Coles, Alasdair J. (2009). "IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)". Journal of Clinical Investigation. 119 (7): 2052–61. doi:10.1172/JCI37878. PMC 2701868. PMID 19546505.
- The CAMMS223 Trial Investigators (2008). "Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis". New England Journal of Medicine. 359 (17): 1786–1801. doi:10.1056/NEJMoa0802670. PMID 18946064.
- The International Multiple Sclerosis Genetics Consortium (2007). "Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study". New England Journal of Medicine. 357 (9): 851–862. doi:10.1056/NEJMoa073493. PMID 17660530.
- Alastair Compston's publications indexed by the Scopus bibliographic database. (subscription required)
- Compston, Alastair (2004). "Editorial". Brain. 127 (8): 1689–1690. doi:10.1093/brain/awh240.
- "No. 61450". The London Gazette (Supplement). 30 December 2015. p. N8.